Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Olink Bioscience Introduces Proseek Multiplex CVD I 96x96

Published: Thursday, October 31, 2013
Last Updated: Thursday, October 31, 2013
Bookmark and Share
A 92 protein biomarker panel for cardiovascular disease.

Olink Bioscience has launched Proseek Multiplex CVD I 96x96, a new protein biomarker panel in the Proseek Multiplex product line which targets cardiovascular disease.

This panel will be an important tool in the search for new multivariate protein biomarker expression patterns that could improve prediction and prognosis of disease.

Cardiovascular disease is the number one cause of death worldwide and a growing health problem that requires massive medical intervention each year. Reversing this trend requires, apart from healthier lifestyles, improved diagnostic and prognostic tools.

New and relevant protein biomarkers are essential components of these tools and therefore a pre-requisite for developing improved and personalized treatment.

Proseek Multiplex CVD I 96x96 is a high throughput multiplex immunoassay which speedily allows analysis of 92 cardiovascular-related protein biomarkers across 96 samples simultaneously without any compromise in data quality. Only one microliter of sample is required, economizing on precious or biobanked clinical material.

When used in conjunction with Fluidigm’s BioMark HD System, Olink Bioscience’s Proseek Multiplex technologies provide researchers with the highest throughput multiplexing solution for protein biomarker discovery in the market.

Typically, researchers are limited to working with a few tens-of-protein biomarkers at a time. Using the BioMark HD System with the Proseek Multiplex CVD I 96x96, a researcher can now obtain results for up to 9,216 reactions in just a few hours.

“It is a very exciting opportunity when Olink can offer a new tool for researchers, clinicians and anyone interested in cardiovascular diseases. It’s well known that all individuals are different and in an ideal world could receive personalized medicine and care. We would like to contribute to fulfilling that dream faster by helping to find new protein expression patterns that could serve as biomarkers” says Andrea Ballagi, Director Commercial Operations at Olink Bioscience.

The Proseek Multiplex CVD I 96x96 panel contains known cardiovascular and inflammatory markers as well as a few exploratory proteins which have great potential as new cardiovascular markers.

The exploratory markers are intracellular proteins which were unexpectedly detected in serum or plasma samples, demonstrating that Proseek Multiplex is a sensitive tool for analyzing proteins in body fluids.

Fluidigm’s BioMark HD System is a multi-application genomics and proteomics platform that provides results equivalent to the gold standards for every respective experimental approach.

The system produces high-quality data from RNA, miRNA and DNA from sample sizes down to the single cell level - and now extends to proteins. The BioMark HD System performs analysis of protein expression, gene expression, copy number variation, SNP genotyping, and digital PCR.

“The cardiovascular panel has already attracted a lot of interest among cardiovascular researchers; we have many customers knocking on our door eager to start analyzing their own clinical samples. We have already performed some initial testing of the panel and the results look very promising. We are very excited about the possibilities Proseek Multiplex CVD I 96x96 offers to the cardiovascular research community and pharmaceutical industry” says Agneta Siegbahn, Professor in Clinical Coagulation Science, Department of Medical Sciences, Uppsala University and Managing Director of Clinical Biomarkers Facility at Science for Life Laboratory in Uppsala, Uppsala University, one of Olink’s service providers.

Proseek Multiplex is based on the proprietary PEA technology developed at Olink. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective antigens.

Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR.

Proseek Multiplex CVD I 96x96 is the second panel from Olink. The company has launched the Proseek Multiplex Oncology I 96x96 product previously this year. Both are for research use only.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

A New European Consortium to Boost our Understanding of IBD
A multi-modal integrated biomarker study Consortium to increase diagnostic precision in detection of the diseases.
Thursday, May 23, 2013
Olink Bioscience Appoints Sigma-Aldrich as Distributor of Duolink
Olink Bioscience will continue to develop the protein biomarker market.
Friday, May 17, 2013
Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Coronavirus Breakthrough
Protein mutation affects spread and virulence of respiratory virus.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos